A US FDA advisory committee handed Eli Lilly & Co. a mixed verdict on its rheumatoid arthritis drug Olumiant (baricitinib), endorsing a 2 mg dose but not a 4 mg version due to a thrombosis signal in clinical trials.
At an April 23 meeting, the Arthritis Advisory Committee voted 10-5 for approval of 2 mg baricitinib, a JAK1/2 inhibitor, for adults with moderately to severely active rheumatoid arthritis (RA)...